Hepion pharmaceuticals to present data on synergistic effects of rencofilstat with anti-pd1 at aacr 2023

Edison, n.j., april 17, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented by its chief scientific officer, daren ure, phd, at the american association for cancer research annual meeting, which is being held april 15-19, 2023, in orlando, florida.
HEPA Ratings Summary
HEPA Quant Ranking